Disappointing study results for Eleven Biotherapeutics
May 18, 2015 at 15:07 PM EDT
Eleven Biotherapeutics Inc. (Nasdaq: EBIO)
reported disappointing results from a Phase 3 study of its dry-eye
disease treatment EBI-005 sending the stock price plummeting $8.35 to $3.62.
